Overview
Penile squamous cell carcinoma (PeSCC) is a rare but significant malignancy arising from the squamous epithelium of the penis. It accounts for over 95% of all primary penile cancers. While rare in developed nations (incidence < 1 per 100,000 men annually), it carries substantial morbidity and psychological impact due to its effect on sexual function, body image, and urinary continence.
Early detection is paramount; localized disease is highly curable with organ-preserving strategies, whereas advanced disease involving lymph nodes or distant metastases carries a guarded prognosis.
Epidemiology and Global Burden
Penile cancer exhibits striking geographic variation.
- High-Incidence Regions: Parts of South America (Brazil, Colombia), sub-Saharan Africa, and Southeast Asia (India, Thailand) report incidence rates of 3.0–8.0 per 100,000 men.
- Low-Incidence Regions: North America, Europe, Australia, and Israel report rates of 0.3–1.0 per 100,000 men.
- Age Distribution: Peak incidence occurs in the 6th and 7th decades of life (median age at diagnosis ~65 years). It is exceedingly rare before age 40.
- Mortality: Despite low incidence, mortality rates remain significant in developing nations due to late presentation and limited access to specialized surgical care.
Etiology and Risk Factors
The development of PeSCC is multifactorial, involving chronic inflammation, viral oncogenesis, and environmental carcinogens. Understanding these factors is crucial for primary prevention.
1. Human Papillomavirus (HPV) Infection
- Role: High-risk HPV types (predominantly HPV-16 and HPV-18) are detected in 30–50% of PeSCC cases.
- Mechanism: Viral oncoproteins E6 and E7 inactivate tumor suppressors p53 and pRb, driving genomic instability.
- Subtypes: HPV-positive tumors are often basaloid or warty histology and tend to occur in younger men. HPV-negative tumors are typically keratinizing (usual type) and associated with chronic inflammation in older men.
2. Phimosis and Chronic Inflammation
- Phimosis (inability to retract the foreskin) is the single strongest non-viral risk factor (Odds Ratio 11–16).
- Mechanism: Accumulation of smegma, chronic balanitis, and recurrent microtrauma create a pro-carcinogenic microenvironment rich in inflammatory cytokines (IL-6, TNF-α) and reactive oxygen species.
3. Lichen Sclerosus (Balantis Xerotica Obliterans – BXO)
- A chronic inflammatory dermatosis causing sclerosis and atrophy of the glans/prepuce.
- Carries a 4–8% lifetime risk of malignant transformation to PeSCC. Regular surveillance is recommended.
4. Poor Hygiene
- Independent risk factor, often intertwined with phimosis. Inadequate cleaning allows carcinogen concentration (smegma components, nitrosamines) and chronic bacterial/viral colonization.
5. Tobacco Smoking
- Dose-dependent risk increase (2–4 fold for heavy smokers).
- Carcinogens (benzo[a]pyrene) are excreted in urine and can contact the glans/foreskin, causing DNA adduct formation. Synergistic with HPV.
6. PUVA Therapy (Psoralen + UVA)
- Men treated with high-dose PUVA for psoriasis have a significantly elevated risk (up to 100-fold) for genital SCC, often with a latency period of 10–15 years.
7. Immunosuppression
- Solid organ transplant recipients (on calcineurin inhibitors) and HIV-positive men have a 5–10x increased risk, earlier onset, and more aggressive disease course.
8. Circumcision Status
- Neonatal/Childhood circumcision is strongly protective (near-zero risk of invasive PeSCC).
- Adult circumcision offers partial protection but does not eliminate risk entirely if performed after puberty/sexual debut.
Precancerous Lesions (Penile Intraepithelial Neoplasia – PeIN)
Before invasive cancer develops, the epithelium may progress through dysplastic stages. The current WHO classification (2022) simplifies terminology:
| Lesion | Clinical Appearance | HPV Association | Progression Risk to Invasive SCC | Management |
|---|---|---|---|---|
| Low-grade PeIN (PeIN 1 / Condyloma / Bowenoid Papulosis) | Warty, papular, pigmented plaques. Often multifocal. | High (HPV 6, 11, 16, 18) | Very Low (< 1–2%) | Observation, Topical therapy (Imiquimod, 5-FU), Laser ablation. |
| High-grade PeIN (PeIN 2/3 / Erythroplasia of Queyrat / Bowenoid Papulosis high-grade) | Velvety, red (erythroplakia), or white (leukoplakia) plaques. Sharp demarcation. | High (HPV 16, 18) | Significant (10–30% over years) | Definitive treatment required: Topical 5-FU / Imiquimod, Laser, Photodynamic Therapy (PDT), or Surgical excision (glansectomy for extensive disease). |
| Differentiated PeIN (dPeIN) | White, hyperkeratotic plaques, often on background of Lichen Sclerosus. | Negative (HPV independent) | High (aggressive biology, p53 mutation) | Surgical excision (often requires glansectomy/partial penectomy). |
Key Clinical Pearl: Erythroplasia of Queyrat (High-grade PeIN of the glans) and Bowen Disease (High-grade PeIN of the shaft) are carcinoma in situ (Tis). They must be treated to prevent invasion.
Clinical Presentation: “How Does It Look?”
This section provides a detailed visual and morphological description of the disease spectrum. Because penile anatomy is external, visual inspection is the primary screening tool. Lesions vary significantly based on histological subtype and anatomical location (Glans/Prepuce vs. Shaft).
1. The “Classic” Invasive SCC (Keratinizing/Usual Type)
| Feature | Usual-type invasive SCC (50–60% of cases) |
|---|---|
| Lesion | Hard, ulcerated, cauliflower-like lump, or a non-healing ulcer with raised edges. |
| Colour | Grey-white or yellow slough over a bleeding base. |
| Location | Glans (about 48%) and foreskin (about 21%). |
| Texture | Firm and fixed; hardness signals invasion. |
| Other signs | Often hidden by a tight foreskin; foul discharge may be the first complaint. |
2. Verrucous Carcinoma (Buschke-Löwenstein Tumor)
| Feature | Verrucous carcinoma |
|---|---|
| Behaviour | Low grade; rarely spreads, but locally destructive. |
| Appearance | Large, warty, cauliflower-like mass with deep clefts. |
| Surface | White-grey and thickened. |
| Growth | Slow, with pushing borders; can burrow into the erectile bodies. |
| Mimic | Giant condyloma (benign). |
3. Basaloid and Warty (HPV-Associated) Variants
- Warty (Condylomatous): Resembles giant genital warts (condylomata acuminata). Papillomatous, exophytic, moist, pink/red surface. Often multifocal.
- Basaloid: Small, solid, bluish-grey or reddish nodules or plaques. Less keratinization, less ulceration early on. Can look deceptively benign or like a small cyst.
- Mixed: Features of both.
4. Carcinoma In Situ (High-Grade PeIN / Tis) – “The Red & White Flags”
- Erythroplasia of Queyrat (Glans): Well-demarcated, bright red (erythematous), velvety, moist, shiny plaque. Borders are sharp. Often asymptomatic or mildly pruritic. Highly suspicious for CIS.
- Bowen Disease (Shaft): Well-demarcated, scaly, erythematous or pigmented plaque. Resembles psoriasis or eczema but fails topical steroids. Surface may be crusted.
- Bowenoid Papulosis: Multiple, small, pigmented (brown/black) or skin-colored papules on shaft/glans. Histologically high-grade but clinically indolent.
5. Differentiated PeIN / Early Invasion (Lichen Sclerosus Background)
- Background: White, sclerotic, atrophic, “cigarette paper” skin (Lichen Sclerosus/BXO).
- Malignant Change: Development of a firm nodule, non-healing ulcer, or thickened hyperkeratotic plaque within the white sclerotic area.
- Significance: High risk of microinvasion; often underestimated on biopsy.
6. Shaft and Meatal Lesions
- Shaft: Usually presents as a nodule, plaque, or ulcer on the penile skin. Higher propensity for lymphatic spread due to richer lymphatic drainage compared to glans.
- Urethral Meatus: Meatal stenosis, bleeding, or a “polypoid” mass protruding from the urethral opening. Suggests urothelial or squamous involvement of the fossa navicularis.
7. Advanced Local Signs (T3/T4)
- Corporal Invasion: Loss of normal penile flaccidity/erection; palpable hardness (induration) extending along the shaft.
- Urethral Invasion: Hematuria, dysuria, urinary frequency, or obstructive symptoms.
- Skin Fixation: Tumor fixed to underlying tunica albuginea or skin (cannot be moved independently).
- Fungating Mass: Large, necrotic, malodorous tumor destroying penile architecture.
Symptoms: What the Patient Experiences
While visual changes are the hallmark, patients experience a constellation of symptoms that often evolve over months. Pain is NOT a reliable early indicator; early PeSCC is frequently painless, leading to dangerous delays.
Primary Local Symptoms
| Symptom | Frequency | Characteristics & Clinical Significance |
|---|---|---|
| Visible Lesion / Lump | ~80–90% | Patient or partner notices a “wart,” “sore,” “bump,” or color change. Most common presenting sign. |
| Non-Healing Ulcer / Sore | ~50–60% | Persists > 4 weeks despite antibiotics/antifungals. Bleeds easily on contact (friable). |
| Bleeding / Spotting | ~30–40% | Blood on underwear, after intercourse, or after retraction of foreskin. Often minimal (spotting). |
| Foul-Smelling Discharge | ~25–35% | Purulent, malodorous discharge trapped under foreskin (phimosis). Indicates necrosis/superinfection. |
| Pain / Tenderness | ~15–25% (Early) ~60% (Late) |
Early: Usually absent or mild irritation. Late: Deep, boring pain = corporal/periosteal invasion. Painful erection (priapism-like) suggests cavernosal invasion. |
| Pruritus (Itching) / Burning | ~20–30% | Common with CIS (Erythroplasia of Queyrat) and inflammatory variants. |
| Phimosis (Acquired/ Worsening) | ~20–30% | Inability to retract foreskin due to tumor infiltration at preputial ring or sclerosis (BXO). New-onset phimosis in an adult male is a red flag. |
| Meatal Stenosis / Urinary Symptoms | ~10–15% | Spraying stream, straining, dysuria, hematuria. Suggests urethral/fossa navicularis involvement. |
| Erectile Dysfunction | Variable | Vascular compromise, corporal fibrosis, or psychological distress. May precede diagnosis. |
Regional Symptoms (Inguinal Lymph Nodes)
- Palpable Groin Lump(s): Most common sign of metastasis (N+). Usually unilateral initially.
- Character: Firm, mobile (early), becoming fixed/matted to fascia (advanced). Not typically tender unless secondarily infected (abscess formation).
- Location: Superficial inguinal nodes (below inguinal ligament), medial to femoral vein. Deep nodal involvement (Cloquet’s node, pelvic nodes) is not palpable.
Systemic Symptoms (Advanced/Metastatic Disease – M1)
- Unexplained weight loss (>10% body weight).
- Fatigue / Anemia.
- Bone pain (vertebrae, pelvis).
- Respiratory symptoms (cough, dyspnea – pulmonary mets).
- Lower extremity edema (iliac/para-aortic nodal obstruction of lymphatics/venous return).
The “Delay Factor”
- Average Patient Delay: 3–6 months (up to >1 year).
- Reasons: Embarrassment, fear of amputation, misdiagnosis as balanitis/STI/eczema, lack of pain.
- Consequence: Each month of delay correlates with upstaging and worse survival.
Diagnostic Workup
1. History and Physical Examination
- Genital Exam: Full retraction of foreskin (lysis of adhesions under topical anesthetic if needed). Document size (cm), location (quadrant: ventral/dorsal, glans/shaft), depth, fixation, urethral involvement.
- Inguinal/Pelvic Nodal Exam: Systematic palpation of superficial/deep inguinal, femoral, and external iliac regions. Note size, number, laterality, mobility, fixation.
- General Exam: Hepatomegaly, lung fields, bone tenderness, lower limb edema.
2. Biopsy: The Diagnostic Gold Standard
| Method | When used | Key point |
|---|---|---|
| Incisional (punch) biopsy | Large or ulcerated lesions. | Sample the living edge, not dead surface. |
| Excisional biopsy | Small (under 1 cm) foreskin or skin lesions. | 2–3 mm margin, or circumcision. |
| Needle biopsy (FNA/core) | Enlarged groin nodes. | Never cut open or drain a node. |
| Pathology report item | Why it matters |
|---|---|
| Subtype | Usual, verrucous, basaloid, warty, papillary or mixed. |
| Grade (G1–G3) | Higher grade means higher risk. |
| Depth of invasion | Separates T1a from T1b. |
| Vessel and nerve invasion | Raise risk of spread. |
| p16 / HPV status | Strong p16 staining suggests HPV-driven cancer. |
| Margins | Whether tumour was fully removed. |
3. Imaging Staging
| Modality | Indication | Details |
|---|---|---|
| MRI Pelvis / Penile MRI | Primary Tumor (T-staging) | Gold standard for local staging. High-resolution T2-weighted sequences define corporal invasion (corpus spongiosum vs cavernosum), urethral invasion, and tunica albuginea breach. Essential for organ-sparing surgery planning. |
| CT Abdomen/Pelvis | Nodal (N) & Distant (M) Staging | Standard for pelvic/retroperitoneal nodes (>8-10mm short axis suspicious), visceral mets, bone lesions. |
| PET-CT (FDG) | Advanced disease (cN+, high grade, >pT2) | Higher sensitivity for occult pelvic/distant mets. Not routine for early (Tis/T1a) disease. |
| Ultrasound (US) + Doppler | Initial nodal assessment | Cheap, non-invasive. Can guide FNA. Operator dependent. Cannot reliably assess deep pelvic nodes. |
| Chest X-ray / CT Chest | Pulmonary Mets | Baseline for intermediate/high risk. |
4. Inguinal Lymph Node Staging Strategies (Critical Decision Point)
The inguinal nodes are the “gateway” for metastasis. Management depends on clinical (cN) and pathological (pN) status.
| Clinical Nodal Status (cN) | Risk Primary Tumor | Recommended Staging Approach |
|---|---|---|
| cN0 (Non-palpable) | Low Risk (pTis, pTa, pT1a G1-2, No LVI) | Surveillance (Strict protocol: q3mo x 2yr, q6mo x 3yr). Or Dynamic Sentinel Node Biopsy (DSNB). |
| cN0 | Intermediate/High Risk (≥pT1b, G3, LVI+, Basaloid/Sarcomatoid) | DSNB (Gold standard) OR Modified Inguinal Lymphadenectomy (MIL). DSNB avoids morbidity of full dissection if negative. |
| cN+ (Palpable, Mobile) | Any | FNA/Core Biopsy confirmation → Radical Inguinal Lymphadenectomy (RIL) / Modified (MIL). Neoadjuvant chemo considered for fixed/bulky nodes (cN3). |
| cN++ (Fixed/Matted) | Any | Biopsy → Neoadjuvant Chemotherapy → Surgery (if response). |
Dynamic Sentinel Node Biopsy (DSNB): Injection of radiocolloid + blue dye at primary tumor site → Lymphoscintigraphy → Gamma probe guided excision of “hot” nodes. Sensitivity >90% in experienced centers. Requires expertise.
Staging: TNM Classification (AJCC 8th Edition / UICC)
Accurate staging dictates treatment and prognosis.
Primary Tumor (pT)
| Stage | Definition | Clinical Implication |
|---|---|---|
| pTis | Carcinoma in situ (High-grade PeIN) | Curable with topical/organ-preserving local therapy. |
| pTa | Non-invasive verrucous carcinoma | Locally destructive, rarely metastasizes. Conservative surgery. |
| pT1a | Invades subepithelial connective tissue WITHOUT LVI, NOT high grade (G3), NOT basaloid/sarcomatoid. | Low Risk nodal mets (~0-5%). Organ preservation standard. Surveillance or DSNB for nodes. |
| pT1b | Invades subepithelial connective tissue WITH LVI OR Grade 3 OR Basaloid/Sarcomatoid histology. | Intermediate/High Risk nodal mets (15-25%). DSNB or MIL indicated. |
| pT2 | Invades corpus spongiosum (urethra) | High Risk nodal mets (30-50%). Partial penectomy + Node staging usually required. |
| pT3 | Invades corpus cavernosum | High Risk. Partial or Total penectomy. Adjuvant therapy consideration. |
| pT4 | Invades adjacent structures (prostate, scrotum, pubic bone, abdominal wall) | Locally Advanced (T4). Multimodal (Chemo-RT + Surgery). Palliative often. |
Regional Lymph Nodes (pN)
- pN0: No nodal metastasis.
- pN1: Metastasis in single inguinal node.
- pN2: Metastasis in multiple (2+) inguinal nodes OR unilateral/bilateral pelvic nodes (without inguinal? rare).
- pN3: Metastasis in pelvic nodes AND inguinal nodes OR extranodal extension (ENE).
Distant Metastasis (M)
- M0: No distant mets.
- M1: Distant mets (Lung, Liver, Bone, Non-regional nodes).
Stage Grouping (Prognostic)
| Stage | TNM groups |
|---|---|
| 0 | Tis or Ta, N0, M0 |
| I | T1a, N0, M0 |
| IIA | T1b or T2, N0, M0 |
| IIB | T3, N0, M0 |
| IIIA | T1–T3, N1, M0 |
| IIIB | T1–T3, N2, M0 |
| IV | T4 any N; or any T with N3; or M1 |
Treatment Modalities: A Risk-Adapted Approach
Treatment balances oncological control (survival) with functional preservation (urinary, sexual, cosmetic). Management should occur in a Multidisciplinary Team (MDT) setting (Urology, Oncology, Radiation Oncology, Pathology, Radiology, Psychology, Plastic Surgery).
1. Management of Precancerous Lesions (PeIN / Tis)
| Treatment | How it is used | Effect | Downsides |
|---|---|---|---|
| Imiquimod 5% cream | 3 times a week for up to 16 weeks. | Clears PeIN in many patients (around 50–70%). | Local inflammation. |
| 5-fluorouracil 5% cream | Once or twice daily for 4–6 weeks. | Similar clearance. | More soreness and erosion. |
| Laser ablation (CO2/Nd:YAG) | For glans or foreskin lesions. | Precise; good cosmetic result. | Recurrence possible. |
| Photodynamic therapy | Light-activated drug; several sessions. | Little scarring. | Less evidence. |
| Circumcision | For foreskin-only lesions. | Curative. | — |
| Glans resurfacing / glansectomy | Extensive glans PeIN or failed treatment. | Lowest recurrence; skin graft reconstruction. | Surgery and altered sensation. |
Check response clinically, with biopsy if needed, at 3–6 months.
2. Organ-Preserving Surgery for Invasive Cancer (T1a-T2)
Goal: Negative margins (>2-5mm ideally) + Cosmesis/Function.
| Procedure | Indication | Technique Highlights | Functional Outcome |
|---|---|---|---|
| Wide Local Excision (WLE) | Small (<1.5-2cm), superficial (T1a), mobile tumors on prepuce/skin/shaft. | Full thickness excision + Primary closure or STSG. | Excellent. |
| Glans Preservation / Glansectomy | Tumors confined to glans (T1-T2), no corporal invasion on MRI. | Excision of glans epithelium ± corpus spongiosum. Reconstruction: STSG (standard), or advanced flaps (e.g., split-thickness graft, acellular matrix, or local flaps like “turn-over” flap). | Voiding: Meatal stenosis risk (10-20%). Sexual: Glans sensation lost; shaft sensation preserved. Erection preserved. Cosmesis good with modern grafts. |
| Partial Penectomy | Tumor involves distal shaft/proximal glans, corporal invasion (T2-T3), but ≥ 2cm (ideally 3cm) of proximal shaft spared. | Amputation at safe margin. Urethra spatulated to create new meatus. | Voiding: Standing possible if stump >3cm. Sexual: Penetration possible if stump adequate. Preserves corpora. |
| Mohs Micrographic Surgery | Selected centers. Tis, T1a. | Real-time margin control. Tissue sparing. | Maximal preservation. Time-consuming. Requires trained dermatologist/urologist team. |
| Laser Excision (CO2/Thulium) | Superficial T1a. | Vaporization with margin assessment. | Good healing. Limited depth control for invasive disease. |
3. Radical Surgery
- Total Penectomy: T3-T4 invading proximal corpora/pelvis, or failed organ preservation. Perineal urethrostomy created. Major psychosexual impact. Requires pre-op counseling + prosthesis discussion (later).
- Pelvic Exenteration: Rare, for T4 involving bladder/prostate/rectum. High morbidity. Palliative intent often.
4. Inguinal Lymph Node Management (Therapeutic)
- Modified Inguinal Lymphadenectomy (MIL / Catalona): Preserves saphenous vein, fascia lata, limits medial boundary (femoral vessels), spares Cremasteric muscle. Standard for cN+ or positive DSNB. Lower lymphedema rate than Radical.
- Radical Inguinal Lymphadenectomy (RIL): Historical. Removes all tissue medial to femoral vein, saphenous vein sacrificed, fascia lata removed. High morbidity (lymphedema 30-50%, wound breakdown 30%). Reserved for bulky/fixed nodes (cN3) or pelvic node dissection.
- Pelvic Lymph Node Dissection (PLND): Indicated if ≥2 positive inguinal nodes (pN2) or Cloquet’s node positive. Open, Laparoscopic, or Robotic.
- Adjuvant Radiation to Groin/Pelvis: Indicated for pN2-3 or Extranodal Extension (ENE+). Improves regional control.
5. Radiation Therapy (Primary or Adjuvant)
| Type | Use | Notes |
|---|---|---|
| Brachytherapy | Organ-preserving option for T1–T2 glans tumours under 4 cm. | Local control about 85–90% at 5 years; good cosmetic results. |
| External beam (IMRT/VMAT) | Larger tumours and lymph node areas when surgery is unsuitable. | — |
| Adjuvant radiotherapy | Positive margins, pN2–3 or spread beyond the node capsule. | Often with chemotherapy. |
| Palliative radiotherapy | Bleeding, painful bone metastases, blocked urinary tract. | Symptom relief. |
6. Systemic Therapy
| Setting | Treatment | Notes |
|---|---|---|
| Before surgery (bulky or fixed nodes, cN2–3) | TIP (paclitaxel, ifosfamide, cisplatin), 4 cycles; or other cisplatin regimens. | Aims to shrink disease for surgery; complete node response predicts good outcome. |
| After surgery (pN2–3, extranodal spread) | Cisplatin-based chemotherapy or chemoradiotherapy. | Evidence is limited. |
| Metastatic, first line | Cisplatin doublets (e.g. with paclitaxel or 5-FU). | Median survival about 9–12 months. |
| Immunotherapy | PD-1 inhibitors; pembrolizumab via tumour-agnostic approvals (MSI-H or TMB-high). | Responses in 15–20%, sometimes long-lasting; no penile-specific approval. |
| Targeted therapy | Cetuximab (EGFR); HER2-targeted drugs in HER2-positive tumours. | Limited activity. |
| Clinical trials | Antibody-drug conjugates, TIL therapy, HPV vaccines. | Recommended for all advanced cases. |
Reconstruction and Rehabilitation
Surgical Reconstruction Options
| Defect | Reconstructive Options | Timing |
|---|---|---|
| Glansectomy Defect | STSG (Thigh/Buttock): Standard. Acellular Dermal Matrix (ADM) + STSG: Better contour. Local Flaps (Turn-over, Dorsal Hood): Glans skin preservation if oncologically safe. |
Immediate (Same sitting). |
| Partial Penectomy (Stump < 2-3cm) | Pedicled Flaps: Gracilis myocutaneous, Anterolateral Thigh (ALT), Rectus Abdominis, SCIP flap. Phalloplasty (Staged): Radial Forearm Free Flap (RFFF) / ALT Free Flap – “Gold Standard” for total reconstruction. Urethral lengthening (buccal mucosa graft). Erectile device (malleable/inflatable) placed 2nd stage. |
Immediate or Delayed (6-12 mo post-oncologic clearance). |
| Total Penectomy | Perineal Urethrostomy (Standard). Phalloplasty (as above). |
Delayed usually preferred (psychosocial adjustment, adjuvant therapy). |
Penile Prosthesis (Implant)
- Indicated for Erectile Dysfunction post-treatment (surgery/RT).
- Malleable (Semi-rigid): Simpler, lower infection risk, good for manual dexterity issues.
- Inflatable (3-piece): More natural flaccidity/erection. Higher mechanical failure/infection risk.
- Timing: Minimum 6-12 months post-radiation/surgery. Infection risk higher in irradiated fields.
Psychosexual Support
- Mandatory referral to sexual health counselor/psychologist.
- Address: Body image, partner intimacy, ejaculatory changes (dry orgasm after pelvic lymphadenectomy/RT), penile shortening, sensation loss.
- Partner involvement encouraged early.
Follow-Up and Survivorship
Recurrence risk is highest in first 2 years (local) and 2-3 years (nodal). Lifetime risk of second primary (HPV-related: oropharyngeal, anal) exists.
Standard Surveillance Protocol (Risk-Adapted)
| Timeframe | Clinical Exam (Primary Site + Nodes) | Imaging | Special Notes |
|---|---|---|---|
| Year 1-2 | Every 3 Months | MRI Penile at 6 & 12 mo (if organ preserved). CT Chest/Abd/Pelvis or PET-CT at 12 mo (Intermediate/High risk). |
Palpate groins meticulously. Patient self-exam education. |
| Year 3-5 | Every 6 Months | CT/PET annually (High risk) or symptom-directed. | Monitor for late RT toxicity (urethral stricture, fibrosis). |
| Year 5+ | Annually | Symptom directed. | Lifelong surveillance for second primaries (Oropharynx, Anus). HPV vaccination discussion (if age eligible). |
Long-Term Toxicities to Monitor
- Urethral Stricture: Post-RT, post-glansectomy, post-partial penectomy. Dilation/Urethroplasty.
- Lymphedema (Genital/Lower Limb): Post-inguinal dissection. Compression garments, physiotherapy, microsurgery (LVA/VLNT).
- Sexual Dysfunction: ED, Peyronie’s (fibrosis), shortening, anorgasmia, partner distress.
- Psychological Distress: Depression, anxiety, fear of recurrence. Screening tools (DT, HADS).
Prevention and Health Promotion
| Measure | Details |
|---|---|
| HPV vaccination | Gardasil 9 at age 11–12 (from 9), catch-up to 26; prevents high-risk HPV infection, genital warts and precancer. |
| Circumcision in childhood | Strongly lowers the risk of invasive penile cancer. |
| Hygiene and phimosis care | Regular cleaning; steroid cream treats most tight foreskins; surgery if it fails. |
| Stop smoking | Lowers risk and helps healing. |
| Lichen sclerosus checks | Yearly examination; biopsy any new hard or ulcerated area. |
| Condoms | Partly protect against HPV. |
Prognosis and Survival Statistics
Data primarily from SEER, NCDB, and European registries (EUROCARE).
| Stage Group | 5-Year Overall Survival (OS) | 5-Year Cancer-Specific Survival (CSS) | Key Determinants |
|---|---|---|---|
| Stage 0 (Tis) | ~95-100% | ~100% | Curable. Recurrence risk local only. |
| Stage I (T1a N0) | ~85-95% | ~95-99% | Excellent. Organ preservation standard. |
| Stage II (T1b-T2 N0) | ~75-85% | ~80-90% | Grade, LVI, depth critical. Nodal staging (DSNB) vital. |
| Stage IIIA (N1) | ~60-70% | ~65-75% | Single node. Adjuvant RT improves control. |
| Stage IIIB (N2) | ~40-55% | ~45-60% | Multiple nodes. ENE = worse. Chemo-RT adjuvant standard. |
| Stage IV (N3 / T4 / M1) | ~15-30% (N3/T4) < 10-15% (M1) |
~20-40% (N3/T4) | Multimodal aggressive therapy. Clinical trials priority. |
Prognostic Factors (Multivariate):
1. Nodal Status (pN): Single most powerful predictor.
2. Extranodal Extension (ENE): Independent adverse factor.
3. Primary Tumor Stage (pT): Depth of invasion (T1a vs T1b vs T2+).
4. Histological Grade / Subtype: Basaloid, Sarcomatoid, G3 = worse.
5. LVI / PNI: Adverse.
6. HPV Status (p16+): Generally favorable prognosis (better response to RT/Chemo, lower nodal metastasis rate for same T-stage) compared to HPV-negative (differentiated) tumors.
Frequently Asked Questions (FAQ)
Q: Is penile cancer contagious? A: No, cancer itself is not contagious.
However, HPV, the virus causing ~50% of cases, is sexually transmitted. Partners should be aware of HPV vaccination and cervical/anal screening guidelines.
Q: Will I lose my penis? A: Not necessarily.
For early stages (Tis, T1a, selected T1b/T2), organ-preserving treatments (glansectomy, laser, brachytherapy, Mohs) are standard and highly effective. Total penectomy is reserved for advanced local disease (T3/T4) or failure of organ preservation.
Q: Does a biopsy spread the cancer? A: No.
This is a myth. Biopsy is essential for diagnosis and staging.
It does not cause metastasis. Incisional drainage of a suspicious lymph node is contraindicated (risk of spread), but needle biopsy (FNA/Core) is safe and standard.
Q: Can I still have sex and father children after treatment?
A: Yes, often.
- Organ preservation: Erections and sensation (shaft) usually preserved. Glans sensation lost if glans removed/resurfaced.
- Partial penectomy: Intercourse possible if sufficient shaft length remains.
- Total penectomy/Phalloplasty: Intercourse possible with penile prosthesis (implanted in reconstructed neophallus).
- Fertility: Surgery/RT to pelvis can affect ejaculation (retrograde/dry orgasm) but sperm production (testes) is usually intact. Sperm banking offered before chemo/RT/pelvic surgery.
Q: What is the “Sentinel Node Biopsy” and do I need it? A: DSNB is a minimally invasive staging procedure for clinically node-negative (cN0) men with intermediate/high-risk primary tumors (pT1b+).
It identifies the first draining node(s). If negative, you avoid a full groin dissection (and its high lymphedema risk).
If positive, you proceed to full dissection. It is the standard of care in expert centers.
Q: I have a white patch on my foreskin/glans (Lichen Sclerosus). Will I get cancer? A:
The risk is low (4-8% lifetime) but real. It requires lifelong surveillance (annual Urology/Dermatology review).
Treat the inflammation (potent topical steroids) to reduce risk. Report any new lump, ulcer, or hardening within the white area immediately.
Q: Are there clinical trials for penile cancer? A: Yes.
Because it is rare, enrollment in clinical trials is strongly encouraged for all stages, especially advanced/recurrent disease. Trials offer access to novel immunotherapies, ADCs, and targeted agents. Ask your oncologist or search ClinicalTrials.gov (keywords: “Penile Cancer”, “Squamous Cell Carcinoma Penis”).
Glossary of Key Terms
| Term | Meaning |
|---|---|
| Balanitis | Inflammation of the glans. |
| BXO | Balanitis xerotica obliterans: genital lichen sclerosus. |
| Corpus cavernosum | Paired erectile bodies. |
| Corpus spongiosum | Erectile body around the urethra, forming the glans. |
| DSNB | Dynamic sentinel node biopsy for groin staging. |
| ENE | Extranodal extension: tumour breaking out of a node; a poor sign. |
| Fossa navicularis | Widened end of the urethra in the glans. |
| Glansectomy | Surgical removal of the glans. |
| HPV | Human papillomavirus. |
| LVI | Lymphovascular invasion. |
| Modified inguinal lymphadenectomy | Groin node removal that spares the saphenous vein. |
| PeIN | Penile intraepithelial neoplasia (precancer). |
| p16 | Stain used as a marker of HPV activity. |
| Phimosis | Foreskin that cannot be pulled back. |
| Smegma | Build-up of skin cells and oils under the foreskin. |
| Tunica albuginea | Fibrous layer around the erectile bodies. |
| Verrucous carcinoma | Low-grade warty SCC that rarely spreads. |
Resources & References (Harvard Style)
- **Albersen, M., et al. (2023) ‘EAU Guidelines on Penile Cancer: 2023 Update’, European Urology, 83(2), pp. 164–180. doi: 10.1016/j.eururo.2022.09.012.
- **Alemany, L. et al. (2016) ‘Role of human papillomavirus in penile cancer worldwide’, European Urology, 69(5), pp. 953–961. doi: 10.1016/j.eururo.2015.09.031.
- **Bracarda, S. et al. (2022) ‘Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 33(8), pp. 774–787. doi: 10.1016/j.annonc.2022.04.005.
- **Burger, M. et al. (2020) ‘Diagnostic and prognostic biomarkers in penile cancer’, Nature Reviews Urology, 17(11), pp. 647–661. doi: 10.1038/s41585-020-0347-8.
- **Chaux, A. and Cubilla, A.L. (2012) ‘Penile carcinoma’, Advances in Anatomic Pathology, 19(2), pp. 96–107. doi: 10.1097/PAP.0b013e318247f8b2.
- **Crook, J.M. et al. (2019) ‘Radiotherapy for penile cancer: A critical review’, Clinical Oncology, 31(11), pp. 719–729. doi: 10.1016/j.clon.2019.06.008.
- **Djajadiningrat, R.S. et al. (2014) ‘Contemporary management of the regional nodes in penile cancer: improvement of survival?’, Journal of Urology, 192(2), pp. 337–343. doi: 10.1016/j.juro.2014.01.070.
- **Gakis, G. et al. (2018) ‘Organ-sparing surgery for penile cancer’, European Urology Focus, 4(3), pp. 348–357. doi: 10.1016/j.euf.2017.06.005.
- **Horenblas, S. et al. (2021) ‘Squamous cell carcinoma of the penis’, The Lancet, 397(10281), pp. 1311–1322. doi: 10.1016/S0140-6736(21)00123-8.
- **Masson, L.F. et al. (2019) ‘Systemic therapy for advanced penile cancer: A systematic review’, European Urology Oncology, 2(4), pp. 388–398. doi: 10.1016/j.euo.2019.01.005.
- **Mistry, S. et al. (2020) ‘Penile cancer: A review of current diagnosis and management’, British Journal of Hospital Medicine, 81(6), pp. 1–8. doi: 10.12968/hmed.2020.0067.
- **National Comprehensive Cancer Network (NCCN) (2023) ‘NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Penile Cancer’, Version 2.2023. Available at: https://www.nccn.org (Accessed: October 2026).
- **Pagliaro, L.C. et al. (2010) ‘Neoadjuvant chemotherapy for penile cancer: The M. D. Anderson experience’, Cancer, 116(24), pp. 5640–5645. doi: 10.1002/cncr.25524.
- **Sarkar, S. et al. (2021) ‘Immunotherapy in penile squamous cell carcinoma: Current landscape and future directions’, Cancers, 13(15), p. 3742. doi: 10.3390/cancers13153742.
- **Spiro, R. et al. (2022) ‘Quality of life and psychosexual outcomes after penile cancer treatment: A systematic review’, Journal of Sexual Medicine, 19(4), pp. 612–625. doi: 10.1016/j.jsxm.2022.01.009.
- **Touijer, K. et al. (2019) ‘Penile cancer: Updates in staging, imaging, and treatment’, Urologic Clinics of North America, 46(3), pp. 331–343. doi: 10.1016/j.ucl.2019.03.003.
- **World Health Organization (WHO) / IARC (2022) WHO Classification of Tumours: Urinary and Male Genital Tumours, 5th Edition. Lyon: IARC Press.
- **Znaor, A. et al. (2019) ‘International trends in penile cancer incidence and mortality’, European Urology, 75(4), pp. 626–633. doi: 10.1016/j.eururo.2018.10.014.